社区
首页
集团介绍
社区
资讯
行情
学堂
TigerGPT
登录
注册
PapiChulo88
IP属地:未知
+关注
帖子 · 36
帖子 · 36
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
PapiChulo88
PapiChulo88
·
2021-12-17
Oh my
BKKT Stock Alert: Why Is Bakkt Plunging
Digital asset manager Bakkt(NYSE:BKKT) is in freefall on Thursday after a recent Securities and Exch
BKKT Stock Alert: Why Is Bakkt Plunging
看
1,059
回复
评论
点赞
1
编组 21备份 2
分享
举报
PapiChulo88
PapiChulo88
·
2021-12-17
Wow
非常抱歉,此主贴已删除
看
1,357
回复
评论
点赞
2
编组 21备份 2
分享
举报
PapiChulo88
PapiChulo88
·
2021-12-17
Wow
@王春龙Bale:
今年前三季度国内外手机销量成绩单:三星全球第一,OV中国霸榜,小米在国内力压苹果1、来自调研机构Canalys的最新数据显示,2021年前三季度,全球手机销量中,三星再次占据第一位,三季度出货量6940万台(累计卖出2.039亿台),占21%市场份额;苹果伴随着iPhone13销量提升,以4920万台出货量(累计卖出1.473亿台),排名第二;小米的出货量4400万台排在第三位(累计卖出1.45亿台),达到14%市场份额;OPPO和vivo排在第四和第五位,出货量分别为3670万台和3420万台。2.在中国市场,vivo和OPPO的销量占据前两位,前三季度的销量分别是5810万台和5310万台,小米力压苹果,在中国市场排名第三位,销量为3700万台。苹果和荣耀分别以2820万台和2110万台的三季度总销量,排名第四和第五位。3.关于销量的提升,Canalys首席分析师Ben Stanton表示:“安卓手机的情况不那么乐观,出货量下降了9%。但供应商的命运喜忧参半。三星的Galaxy A系列设备再次供不应求。小米也看到了供不应求的局面,但部分原因是上一季度表现抢眼,耗尽了可用库存。相比之下,上一季度OPPO和vivo在第三季度因新冠病毒肆虐南亚核心市场而反弹。4.但在全球前五位中,三星和小米的销量呈现下降趋势,尤其是三星下降了14%左右,而在正增长幅度上,OPPO增长了18%,苹果增长了14%,vivo增长了8%。在正增长前五位中,中国手机品牌占据两位。$小米集团-W(01810)$$苹果(AAPL)$
今年前三季度国内外手机销量成绩单:三星全球第一,OV中国霸榜,小米在国内力压苹果1、来自调研机构Canalys的最新数据显示,2021年前三季度,全球手机销量中,三星再次占据第一位,三季度出货量6940万台(累计卖出2.039亿台),占21%市场份额;苹果伴随着iPhone13销量提升,以4920万台出货量(累计卖出1.473亿台),排名第二;小米的出货量4400万台排在第三位(累计卖出1.45亿台),达到14%市场份额;OPPO和vivo排在第四和第五位,出货量分别为3670万台和3420万台。2.在中国市场,vivo和OPPO的销量占据前两位,前三季度的销量分别是5810万台和5310万台,小米力压苹果,在中国市场排名第三位,销量为3700万台。苹果和荣耀分别以2820万台和2110万台的三季度总销量,排名第四和第五位。3.关于销量的提升,Canalys首席分析师Ben Stanton表示:“安卓手机的情况不那么乐观,出货量下降了9%。但供应商的命运喜忧参半。三星的Galaxy A系列设备再次供不应求。小米也看到了供不应求的局面,但部分原因是上一季度表现抢眼,耗尽了可用库存。相比之下,上一季度OPPO和vivo在第三季度因新冠病毒肆虐南亚核心市场而反弹。4.但在全球前五位中,三星和小米的销量呈现下降趋势,尤其是三星下降了14%左右,而在正增长幅度上,OPPO增长了18%,苹果增长了14%,vivo增长了8%。在正增长前五位中,中国手机品牌占据两位。$小米集团-W(01810)$$苹果(AAPL)$
看
1,324
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
PapiChulo88
PapiChulo88
·
2021-12-17
🥺
@名字就是这样:
$Bionano Genomics(BNGO)$买定离手[可爱] [可爱]
$Bionano Genomics(BNGO)$买定离手[可爱] [可爱]
看
1,311
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
PapiChulo88
PapiChulo88
·
2021-12-17
😭
非常抱歉,此主贴已删除
看
1,088
回复
1
点赞
2
编组 21备份 2
分享
举报
PapiChulo88
PapiChulo88
·
2021-11-09
$Naked Brand(NAKD)$
is up!
看
1,444
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
PapiChulo88
PapiChulo88
·
2021-11-05
Oh my
Bionano Genomics stock tanked more than 8% in premarket trading
Bionano Genomics stock tanked more than 8% in premarket trading after Bionano Genomics Q3 net loss $
Bionano Genomics stock tanked more than 8% in premarket trading
看
1,167
回复
评论
点赞
1
编组 21备份 2
分享
举报
PapiChulo88
PapiChulo88
·
2021-11-01
$HCW Biologics Inc.(HCWB)$
Hold! It will be up again
看
1,476
回复
评论
点赞
1
编组 21备份 2
分享
举报
PapiChulo88
PapiChulo88
·
2021-11-01
$Naked Brand(NAKD)$
What’s happening
看
1,204
回复
1
点赞
1
编组 21备份 2
分享
举报
PapiChulo88
PapiChulo88
·
2021-10-27
It’s a good time to buy
Trump stocks fell sharply in premarket trading
Trump stocks fell sharply in premarket trading,Phunware slid nearly 10%,Creatd and DWAC slid over 6%
Trump stocks fell sharply in premarket trading
看
874
回复
评论
点赞
5
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3576458191145383","uuid":"3576458191145383","gmtCreate":1613364167181,"gmtModify":1623129571224,"name":"PapiChulo88","pinyin":"papichulo88","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/c96f770d89e4ec52569d75c168c27695","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":4,"headSize":12,"tweetSize":36,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.07.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":690797621,"gmtCreate":1639707049357,"gmtModify":1639708339012,"author":{"id":"3576458191145383","authorId":"3576458191145383","name":"PapiChulo88","avatar":"https://static.tigerbbs.com/c96f770d89e4ec52569d75c168c27695","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576458191145383","authorIdStr":"3576458191145383"},"themes":[],"htmlText":"Oh my ","listText":"Oh my ","text":"Oh my","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690797621","repostId":"1155708308","repostType":2,"repost":{"id":"1155708308","kind":"news","pubTimestamp":1639706709,"share":"https://www.laohu8.com/m/news/1155708308?lang=&edition=full","pubTime":"2021-12-17 10:05","market":"us","language":"en","title":"BKKT Stock Alert: Why Is Bakkt Plunging","url":"https://stock-news.laohu8.com/highlight/detail?id=1155708308","media":"InvestorPlace","summary":"Digital asset manager Bakkt(NYSE:BKKT) is in freefall on Thursday after a recent Securities and Exch","content":"<p>Digital asset manager <b>Bakkt</b>(NYSE:<b><u>BKKT</u></b>) is in freefall on Thursday after a recent Securities and Exchange Commission (SEC) filing has investors spooked. BKKT stock is down big today, just two months after its October SPAC debut.</p>\n<p>So, what’s causing this slump in Bakkt?</p>\n<p>Bakkt is falling victim to an apparent PIPE (private investment in public equity) selloff. Yesterday, Bakkt filed an S-1 registration statement with the SEC, allowing early investors in the company freedom to sell their stake. Consequently, they did. Bakkt has already shed more than 31% of its share price as investors cool off on the once red-hot stock.</p>\n<p>Founded in 2018, Bakkt went public just this past October. A week after its debut, BKKT went as high as $42.52 per share amid sky-high investor interest. However, it seems the party is over. Accounting for today’s losses so far, Bakkt is trending a bit below $10 at the time of writing.</p>\n<p>What else do you need to know about Bakkt’s dive?</p>\n<p><b>BKKT Stock Flounders as Bears Come Out on Top</b></p>\n<p>While the PIPE unlocking is wreaking havoc on shareholder wallets, Bakkt is grasping at straws to put a stop to the decline.</p>\n<p>The Georgia-based company is best known for its digital asset exchange platform. Bakkt is the latest crypto exchange making waves after its app launched under the guidance of parent company Intercontinental Exchange.</p>\n<p>Unfortunately, since its Oct. 25 peak, it’s been a downhill story for the crypto exchange. Even despite a headline-grabbing integration announcement with <b>Alphabet’s</b> Google Pay, Bakkt can’t seem to reverse its fortune.</p>\n<p>Additionally, just this week Bakkt began offering <b>WyndhamRewards</b> members the ability to convert reward points into cash deposited directly into their accounts. Unfortunately, it was seemingly to no avail.</p>\n<p>Time will tell just how far BKKT will drop. However, for those looking for cheap crypto exposure, a rock-bottom entry point like this could be appealing.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BKKT Stock Alert: Why Is Bakkt Plunging</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBKKT Stock Alert: Why Is Bakkt Plunging\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-17 10:05 GMT+8 <a href=https://investorplace.com/2021/12/bkkt-stock-alert-why-is-bakkt-plunging-today/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Digital asset manager Bakkt(NYSE:BKKT) is in freefall on Thursday after a recent Securities and Exchange Commission (SEC) filing has investors spooked. BKKT stock is down big today, just two months ...</p>\n\n<a href=\"https://investorplace.com/2021/12/bkkt-stock-alert-why-is-bakkt-plunging-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BKKT":"Bakkt Holdings, Inc."},"source_url":"https://investorplace.com/2021/12/bkkt-stock-alert-why-is-bakkt-plunging-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1155708308","content_text":"Digital asset manager Bakkt(NYSE:BKKT) is in freefall on Thursday after a recent Securities and Exchange Commission (SEC) filing has investors spooked. BKKT stock is down big today, just two months after its October SPAC debut.\nSo, what’s causing this slump in Bakkt?\nBakkt is falling victim to an apparent PIPE (private investment in public equity) selloff. Yesterday, Bakkt filed an S-1 registration statement with the SEC, allowing early investors in the company freedom to sell their stake. Consequently, they did. Bakkt has already shed more than 31% of its share price as investors cool off on the once red-hot stock.\nFounded in 2018, Bakkt went public just this past October. A week after its debut, BKKT went as high as $42.52 per share amid sky-high investor interest. However, it seems the party is over. Accounting for today’s losses so far, Bakkt is trending a bit below $10 at the time of writing.\nWhat else do you need to know about Bakkt’s dive?\nBKKT Stock Flounders as Bears Come Out on Top\nWhile the PIPE unlocking is wreaking havoc on shareholder wallets, Bakkt is grasping at straws to put a stop to the decline.\nThe Georgia-based company is best known for its digital asset exchange platform. Bakkt is the latest crypto exchange making waves after its app launched under the guidance of parent company Intercontinental Exchange.\nUnfortunately, since its Oct. 25 peak, it’s been a downhill story for the crypto exchange. Even despite a headline-grabbing integration announcement with Alphabet’s Google Pay, Bakkt can’t seem to reverse its fortune.\nAdditionally, just this week Bakkt began offering WyndhamRewards members the ability to convert reward points into cash deposited directly into their accounts. Unfortunately, it was seemingly to no avail.\nTime will tell just how far BKKT will drop. However, for those looking for cheap crypto exposure, a rock-bottom entry point like this could be appealing.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1059,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690704308,"gmtCreate":1639706305167,"gmtModify":1639706953509,"author":{"id":"3576458191145383","authorId":"3576458191145383","name":"PapiChulo88","avatar":"https://static.tigerbbs.com/c96f770d89e4ec52569d75c168c27695","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576458191145383","authorIdStr":"3576458191145383"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690704308","repostId":"1172405131","repostType":4,"isVote":1,"tweetType":1,"viewCount":1357,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690705530,"gmtCreate":1639706274621,"gmtModify":1639706274754,"author":{"id":"3576458191145383","authorId":"3576458191145383","name":"PapiChulo88","avatar":"https://static.tigerbbs.com/c96f770d89e4ec52569d75c168c27695","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576458191145383","authorIdStr":"3576458191145383"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690705530","repostId":"604088904","repostType":1,"repost":{"id":604088904,"gmtCreate":1639281345798,"gmtModify":1639358988582,"author":{"id":"3494378197296027","authorId":"3494378197296027","name":"王春龙Bale","avatar":"https://static.tigerbbs.com/11e561afcd6e41b0d7953fc87b7c54a9","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3494378197296027","authorIdStr":"3494378197296027"},"themes":[],"htmlText":"今年前三季度国内外手机销量成绩单:三星全球第一,OV中国霸榜,小米在国内力压苹果1、来自调研机构Canalys的最新数据显示,2021年前三季度,全球手机销量中,三星再次占据第一位,三季度出货量6940万台(累计卖出2.039亿台),占21%市场份额;苹果伴随着iPhone13销量提升,以4920万台出货量(累计卖出1.473亿台),排名第二;小米的出货量4400万台排在第三位(累计卖出1.45亿台),达到14%市场份额;OPPO和vivo排在第四和第五位,出货量分别为3670万台和3420万台。2.在中国市场,vivo和OPPO的销量占据前两位,前三季度的销量分别是5810万台和5310万台,小米力压苹果,在中国市场排名第三位,销量为3700万台。苹果和荣耀分别以2820万台和2110万台的三季度总销量,排名第四和第五位。3.关于销量的提升,Canalys首席分析师Ben Stanton表示:“安卓手机的情况不那么乐观,出货量下降了9%。但供应商的命运喜忧参半。三星的Galaxy A系列设备再次供不应求。小米也看到了供不应求的局面,但部分原因是上一季度表现抢眼,耗尽了可用库存。相比之下,上一季度OPPO和vivo在第三季度因新冠病毒肆虐南亚核心市场而反弹。4.但在全球前五位中,三星和小米的销量呈现下降趋势,尤其是三星下降了14%左右,而在正增长幅度上,OPPO增长了18%,苹果增长了14%,vivo增长了8%。在正增长前五位中,中国手机品牌占据两位。<a target=\"_blank\" href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$</a><a target=\"_blank\" href=\"https://laohu8.com/S/AAPL\">$苹果(AAPL)$</a>","listText":"今年前三季度国内外手机销量成绩单:三星全球第一,OV中国霸榜,小米在国内力压苹果1、来自调研机构Canalys的最新数据显示,2021年前三季度,全球手机销量中,三星再次占据第一位,三季度出货量6940万台(累计卖出2.039亿台),占21%市场份额;苹果伴随着iPhone13销量提升,以4920万台出货量(累计卖出1.473亿台),排名第二;小米的出货量4400万台排在第三位(累计卖出1.45亿台),达到14%市场份额;OPPO和vivo排在第四和第五位,出货量分别为3670万台和3420万台。2.在中国市场,vivo和OPPO的销量占据前两位,前三季度的销量分别是5810万台和5310万台,小米力压苹果,在中国市场排名第三位,销量为3700万台。苹果和荣耀分别以2820万台和2110万台的三季度总销量,排名第四和第五位。3.关于销量的提升,Canalys首席分析师Ben Stanton表示:“安卓手机的情况不那么乐观,出货量下降了9%。但供应商的命运喜忧参半。三星的Galaxy A系列设备再次供不应求。小米也看到了供不应求的局面,但部分原因是上一季度表现抢眼,耗尽了可用库存。相比之下,上一季度OPPO和vivo在第三季度因新冠病毒肆虐南亚核心市场而反弹。4.但在全球前五位中,三星和小米的销量呈现下降趋势,尤其是三星下降了14%左右,而在正增长幅度上,OPPO增长了18%,苹果增长了14%,vivo增长了8%。在正增长前五位中,中国手机品牌占据两位。<a target=\"_blank\" href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$</a><a target=\"_blank\" href=\"https://laohu8.com/S/AAPL\">$苹果(AAPL)$</a>","text":"今年前三季度国内外手机销量成绩单:三星全球第一,OV中国霸榜,小米在国内力压苹果1、来自调研机构Canalys的最新数据显示,2021年前三季度,全球手机销量中,三星再次占据第一位,三季度出货量6940万台(累计卖出2.039亿台),占21%市场份额;苹果伴随着iPhone13销量提升,以4920万台出货量(累计卖出1.473亿台),排名第二;小米的出货量4400万台排在第三位(累计卖出1.45亿台),达到14%市场份额;OPPO和vivo排在第四和第五位,出货量分别为3670万台和3420万台。2.在中国市场,vivo和OPPO的销量占据前两位,前三季度的销量分别是5810万台和5310万台,小米力压苹果,在中国市场排名第三位,销量为3700万台。苹果和荣耀分别以2820万台和2110万台的三季度总销量,排名第四和第五位。3.关于销量的提升,Canalys首席分析师Ben Stanton表示:“安卓手机的情况不那么乐观,出货量下降了9%。但供应商的命运喜忧参半。三星的Galaxy A系列设备再次供不应求。小米也看到了供不应求的局面,但部分原因是上一季度表现抢眼,耗尽了可用库存。相比之下,上一季度OPPO和vivo在第三季度因新冠病毒肆虐南亚核心市场而反弹。4.但在全球前五位中,三星和小米的销量呈现下降趋势,尤其是三星下降了14%左右,而在正增长幅度上,OPPO增长了18%,苹果增长了14%,vivo增长了8%。在正增长前五位中,中国手机品牌占据两位。$小米集团-W(01810)$$苹果(AAPL)$","images":[{"img":"https://static.tigerbbs.com/4c8eac165d2046bc5473d6c25feeb539","width":"1080","height":"1611"},{"img":"https://static.tigerbbs.com/869ac9acb00e1ad37f873af33834623c","width":"1000","height":"705"},{"img":"https://static.tigerbbs.com/64235d5f2b7b09ae46076a8da4715361","width":"1000","height":"643"}],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/604088904","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1324,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690701170,"gmtCreate":1639706008518,"gmtModify":1639706008640,"author":{"id":"3576458191145383","authorId":"3576458191145383","name":"PapiChulo88","avatar":"https://static.tigerbbs.com/c96f770d89e4ec52569d75c168c27695","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576458191145383","authorIdStr":"3576458191145383"},"themes":[],"htmlText":"🥺","listText":"🥺","text":"🥺","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690701170","repostId":"607460968","repostType":1,"repost":{"id":607460968,"gmtCreate":1639579382045,"gmtModify":1639704589453,"author":{"id":"3559804133107604","authorId":"3559804133107604","name":"名字就是这样","avatar":"https://static.tigerbbs.com/ecd5018dcfd0f98e2db33cd5b25c541c","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3559804133107604","authorIdStr":"3559804133107604"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNGO\">$Bionano Genomics(BNGO)$</a>买定离手[可爱] [可爱] ","listText":"<a href=\"https://laohu8.com/S/BNGO\">$Bionano Genomics(BNGO)$</a>买定离手[可爱] [可爱] ","text":"$Bionano Genomics(BNGO)$买定离手[可爱] [可爱]","images":[{"img":"https://static.tigerbbs.com/46343c9bd8b490ff7fcdbb048c54a4e2","width":"750","height":"1334"}],"top":1,"highlighted":2,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607460968","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1311,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690703919,"gmtCreate":1639705922440,"gmtModify":1639705922561,"author":{"id":"3576458191145383","authorId":"3576458191145383","name":"PapiChulo88","avatar":"https://static.tigerbbs.com/c96f770d89e4ec52569d75c168c27695","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576458191145383","authorIdStr":"3576458191145383"},"themes":[],"htmlText":"😭","listText":"😭","text":"😭","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/690703919","repostId":"2192920942","repostType":4,"isVote":1,"tweetType":1,"viewCount":1088,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844822526,"gmtCreate":1636417891085,"gmtModify":1636417891215,"author":{"id":"3576458191145383","authorId":"3576458191145383","name":"PapiChulo88","avatar":"https://static.tigerbbs.com/c96f770d89e4ec52569d75c168c27695","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576458191145383","authorIdStr":"3576458191145383"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NAKD\">$Naked Brand(NAKD)$</a>is up! ","listText":"<a href=\"https://laohu8.com/S/NAKD\">$Naked Brand(NAKD)$</a>is up! ","text":"$Naked Brand(NAKD)$is up!","images":[{"img":"https://static.tigerbbs.com/5082d8e62ecba911cc847ce3b96ab592","width":"1284","height":"2538"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844822526","isVote":1,"tweetType":1,"viewCount":1444,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":846430950,"gmtCreate":1636102914954,"gmtModify":1636102915010,"author":{"id":"3576458191145383","authorId":"3576458191145383","name":"PapiChulo88","avatar":"https://static.tigerbbs.com/c96f770d89e4ec52569d75c168c27695","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576458191145383","authorIdStr":"3576458191145383"},"themes":[],"htmlText":"Oh my ","listText":"Oh my ","text":"Oh my","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/846430950","repostId":"1194946622","repostType":4,"repost":{"id":"1194946622","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636101187,"share":"https://www.laohu8.com/m/news/1194946622?lang=&edition=full","pubTime":"2021-11-05 16:33","market":"us","language":"en","title":"Bionano Genomics stock tanked more than 8% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1194946622","media":"Tiger Newspress","summary":"Bionano Genomics stock tanked more than 8% in premarket trading after Bionano Genomics Q3 net loss $","content":"<p>Bionano Genomics stock tanked more than 8% in premarket trading after Bionano Genomics Q3 net loss $20.753M, sales $4.66M beat $4.23M estimate.</p>\n<p><img src=\"https://static.tigerbbs.com/459633281a2e1ef6cef18931e8ba2b92\" tg-width=\"848\" tg-height=\"619\" width=\"100%\" height=\"auto\"></p>\n<p><b>Bionano Genomics, Inc.</b> reported financial results and business achievements for the quarter ended September 30, 2021 and highlighted recent corporate updates.</p>\n<p><i>– Acquisition of BioDiscovery transforms Bionano from the structural variation company into a data solutions provider with the potential to offer the most comprehensive variant analysis platform in genomics</i></p>\n<p><i>– Total revenue of$4.7 million, a 112% year-over-year total revenue increase, driven by growth in the Saphyr® installed base</i></p>\n<p><i>– Record number of Saphyr shipments and installations for any quarter to date</i></p>\n<p><i>– Launched protocols for ultra-high molecular weight DNA isolation from amniocentesis and chorionic villus sampling (CVS) for prenatal applications</i></p>\n<p><i>– Remaining 2021 milestones on track</i></p>\n<p><i>– Strong balance sheet with$326.1 millionin cash and short term investments as ofSeptember 30, 2021</i></p>\n<p>“We had the strongest quarter in Bionano’s history with a record number of Saphyr shipments and installations, including adoptions at several notable sites, including leading hospitals, cytogenetics labs and academic medical centers around the world. With the acquisition of BioDiscovery, a leading software company with best-in-class solutions for analysis, visualization, interpretation and reporting of genomics data. for microarray and next-generation sequencing (NGS), we are transitioningBionano Genomicsfrom being the structural variation company into a data solutions provider. We believe this will enable access to an expanded market opportunity by leveraging the NGS market through software. We are extremely pleased with the progress we are making and the fact that outstanding leaders are joining Bionano to join us in transforming the way the world sees the genome,” commentedErik Holmlin, PhD, Chief Executive Officer ofBionano Genomics.</p>\n<p>Chris Stewart, Chief Financial Officer of Bionano added: “Q3 was another excellent quarter. We continued to achieve meaningful year-over-year revenue growth and maintained a strong balance sheet with$326 millionof cash and marketable securities as of the quarter-end. We also remain on track to achieve the milestones we laid out in the first quarter of 2021.”</p>\n<p><b>Key Business Highlights in Q3</b></p>\n<p>The Company executed on its commercialization strategy, built scientific momentum by presenting data at key scientific meetings and drove utilization of Saphyr at key institutions across the globe, with the following highlights:</p>\n<p>–<b> Expanded the installed base of Saphyr systems from 121 at the end of Q2 to 141 at the end of Q3</b>. During the quarter endedSeptember 30,2021, we shipped a total of 24 Saphyr systems to the field, compared to 11 systems shipped in the same quarter in 2020.</p>\n<p>–<b> Sold 3,969 nanochannel array flow cells during the quarter endedSeptember 30, 2021,</b>which is the most flow cells sold in any quarter ever and represents 122% growth over the same quarter in 2020.</p>\n<p>–<b> Commercial release of solutions for isolation of ultra-high molecular weight DNA for prenatal applications</b>supporting the use of samples derived from amniocentesis and CVS. Bionano Prep SP Amnio and CVS Culture DNA Isolation Protocol supports both fresh cultures and cryopreserved cells, which expands the markets served for OGM.</p>\n<p>– <b>OGM with Saphyr was adopted at several notable cytogenetics laboratories and academic medical centers</b>inthe United States, including Brigham & Woman’s Hospital, which is using OGM to identify structural variations in constitutional and cancer applications. Outside the US, Saphyr was adopted inAustralia,EuropeandChina.</p>\n<p>–<b> The largest clinical research study to date evaluating OGM was published in</b><b><i>The Journal of Molecular Diagnostics</i></b>for a rare muscle disease, facioscapulohumeral muscular dystrophy, or FSHD, in about 351 patients. The results demonstrated that OGM provided data more quickly, accurately, and reproducibly than the current gold standard method of Southern blot analysis. The findings support the rationale for adopting OGM as an alternative to Southern blot analysis as OGM had a greater sizing accuracy as well as a greater than 99% concordance with Southern blot analysis.</p>\n<p>–<b> NuProbe Global, a global molecular diagnostics leader, adopted Saphyr to be integrated their proprietary tools,</b>Quantitative Amplicon Sequencing (QASeq) and Blocker Displacement Amplification (BDA), for research and development efforts in reproductive health and oncology liquid biopsies.</p>\n<p>–<b> Saphyr customers and Bionano conducted 10 presentations at the Annual Cancer Genomics Consortium Meeting inmid-August 2021,</b>highlighting the benefits of OGM for clinical research applications in solid tumor analysis, hematological malignancies, products of conception, prenatal and postnatal constitutional genetics. More than 500 participants from around the globe attended virtually, highlighting the strong interest in OGM for cancer genomics.</p>\n<p>– <b>Bionano customers presented 11 presentations on OGM at theEuropean Society of Human Genetics(ESHG) meeting in lateAugust 2021</b>, demonstrating the clinical utility of OGM across many therapeutic application areas, along with the unique capabilities of Bionano’s Saphyr®system to detect all classes of structural variants, across the genome, at a superior resolution relative to traditional techniques.</p>\n<p>– <b>Added exceptional talent across commercial leadership functions,</b>includingAmanda Lettmannas Vice President of Global Customer Experience,Alex Helmas Vice President Strategic Product Marketing,Stephanie Hoyleas Vice President Corporate Marketing,Amanda Hernandezas Vice President of Global Sales Training and Development,Justin Leightonas Vice President and General Manager,Lineagen, andBob Hertsenbergas North America Sales Director.</p>\n<p><b>Financial Highlights</b></p>\n<p>–<b> Total revenue for the third quarter of 2021 was$4.7 million,</b>up 21% from$3.9 millionin the second quarter and up 112% from$2.2 millionin the same period of 2020. The sequential increase was driven by increased demand for our Saphyr optical genome mapping solutions, including increased instrument sales and greater demand for our reagent rental program and consumables. The year-over-year increase was driven by both higher product sales and by the addition of revenue fromLineagen.</p>\n<p>–<b> Gross margin for the third quarter of 2021 was 24.8%,</b>compared to 37.3% in the prior quarter and 33.4% from the third quarter of 2020. The decrease was primarily due to an increase in laboratory and warranty related expense that are expected to be non-recurring.</p>\n<p>–<b> Third quarter operating expense was$21.8 million,</b>compared to$17.9 million in the prior quarter and$11.0 millionin the third quarter of 2020. The sequential increase was mainly due to a$1.8 millionincrease in headcount and related expenses and a$1.5 millionincrease in Research and Development expenses related to expanding our supply chain to produce higher volumes. Third quarter operating expense included$2.8 millionof non-cash stock-based compensation. The year-over-year increase was primarily due to increased headcount-related spending as we build out all facets of our organization to support our expected commercial progress and increased research and development costs.</p>\n<p>– <b>AtSeptember 30, 2021, the Company had cash, cash equivalents, and short-term investments of$326.1 million</b>compared to cash and cash equivalents of$38.4 millionatDecember 31, 2020. The increase in cash is primarily due to the equity raises that were completed in the first quarter of 2021.</p>\n<p><b>Remaining Anticipated Milestones for 2021 – Initiatives to Drive Global Adoption of Saphyr</b></p>\n<p>– 4Q21: Interim publication of results from pediatric clinical study</p>\n<p>– 4Q21: Validation of LDTs by 3 sites in both our prenatal clinical study and our pediatric clinical study</p>\n<p>– 4Q21: Initial prototype of next gen high throughput Saphyr</p>\n<p>– 4Q21: Reach installed base of 150 systems to achieve a 50% increase over year end 2020</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bionano Genomics stock tanked more than 8% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBionano Genomics stock tanked more than 8% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-05 16:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Bionano Genomics stock tanked more than 8% in premarket trading after Bionano Genomics Q3 net loss $20.753M, sales $4.66M beat $4.23M estimate.</p>\n<p><img src=\"https://static.tigerbbs.com/459633281a2e1ef6cef18931e8ba2b92\" tg-width=\"848\" tg-height=\"619\" width=\"100%\" height=\"auto\"></p>\n<p><b>Bionano Genomics, Inc.</b> reported financial results and business achievements for the quarter ended September 30, 2021 and highlighted recent corporate updates.</p>\n<p><i>– Acquisition of BioDiscovery transforms Bionano from the structural variation company into a data solutions provider with the potential to offer the most comprehensive variant analysis platform in genomics</i></p>\n<p><i>– Total revenue of$4.7 million, a 112% year-over-year total revenue increase, driven by growth in the Saphyr® installed base</i></p>\n<p><i>– Record number of Saphyr shipments and installations for any quarter to date</i></p>\n<p><i>– Launched protocols for ultra-high molecular weight DNA isolation from amniocentesis and chorionic villus sampling (CVS) for prenatal applications</i></p>\n<p><i>– Remaining 2021 milestones on track</i></p>\n<p><i>– Strong balance sheet with$326.1 millionin cash and short term investments as ofSeptember 30, 2021</i></p>\n<p>“We had the strongest quarter in Bionano’s history with a record number of Saphyr shipments and installations, including adoptions at several notable sites, including leading hospitals, cytogenetics labs and academic medical centers around the world. With the acquisition of BioDiscovery, a leading software company with best-in-class solutions for analysis, visualization, interpretation and reporting of genomics data. for microarray and next-generation sequencing (NGS), we are transitioningBionano Genomicsfrom being the structural variation company into a data solutions provider. We believe this will enable access to an expanded market opportunity by leveraging the NGS market through software. We are extremely pleased with the progress we are making and the fact that outstanding leaders are joining Bionano to join us in transforming the way the world sees the genome,” commentedErik Holmlin, PhD, Chief Executive Officer ofBionano Genomics.</p>\n<p>Chris Stewart, Chief Financial Officer of Bionano added: “Q3 was another excellent quarter. We continued to achieve meaningful year-over-year revenue growth and maintained a strong balance sheet with$326 millionof cash and marketable securities as of the quarter-end. We also remain on track to achieve the milestones we laid out in the first quarter of 2021.”</p>\n<p><b>Key Business Highlights in Q3</b></p>\n<p>The Company executed on its commercialization strategy, built scientific momentum by presenting data at key scientific meetings and drove utilization of Saphyr at key institutions across the globe, with the following highlights:</p>\n<p>–<b> Expanded the installed base of Saphyr systems from 121 at the end of Q2 to 141 at the end of Q3</b>. During the quarter endedSeptember 30,2021, we shipped a total of 24 Saphyr systems to the field, compared to 11 systems shipped in the same quarter in 2020.</p>\n<p>–<b> Sold 3,969 nanochannel array flow cells during the quarter endedSeptember 30, 2021,</b>which is the most flow cells sold in any quarter ever and represents 122% growth over the same quarter in 2020.</p>\n<p>–<b> Commercial release of solutions for isolation of ultra-high molecular weight DNA for prenatal applications</b>supporting the use of samples derived from amniocentesis and CVS. Bionano Prep SP Amnio and CVS Culture DNA Isolation Protocol supports both fresh cultures and cryopreserved cells, which expands the markets served for OGM.</p>\n<p>– <b>OGM with Saphyr was adopted at several notable cytogenetics laboratories and academic medical centers</b>inthe United States, including Brigham & Woman’s Hospital, which is using OGM to identify structural variations in constitutional and cancer applications. Outside the US, Saphyr was adopted inAustralia,EuropeandChina.</p>\n<p>–<b> The largest clinical research study to date evaluating OGM was published in</b><b><i>The Journal of Molecular Diagnostics</i></b>for a rare muscle disease, facioscapulohumeral muscular dystrophy, or FSHD, in about 351 patients. The results demonstrated that OGM provided data more quickly, accurately, and reproducibly than the current gold standard method of Southern blot analysis. The findings support the rationale for adopting OGM as an alternative to Southern blot analysis as OGM had a greater sizing accuracy as well as a greater than 99% concordance with Southern blot analysis.</p>\n<p>–<b> NuProbe Global, a global molecular diagnostics leader, adopted Saphyr to be integrated their proprietary tools,</b>Quantitative Amplicon Sequencing (QASeq) and Blocker Displacement Amplification (BDA), for research and development efforts in reproductive health and oncology liquid biopsies.</p>\n<p>–<b> Saphyr customers and Bionano conducted 10 presentations at the Annual Cancer Genomics Consortium Meeting inmid-August 2021,</b>highlighting the benefits of OGM for clinical research applications in solid tumor analysis, hematological malignancies, products of conception, prenatal and postnatal constitutional genetics. More than 500 participants from around the globe attended virtually, highlighting the strong interest in OGM for cancer genomics.</p>\n<p>– <b>Bionano customers presented 11 presentations on OGM at theEuropean Society of Human Genetics(ESHG) meeting in lateAugust 2021</b>, demonstrating the clinical utility of OGM across many therapeutic application areas, along with the unique capabilities of Bionano’s Saphyr®system to detect all classes of structural variants, across the genome, at a superior resolution relative to traditional techniques.</p>\n<p>– <b>Added exceptional talent across commercial leadership functions,</b>includingAmanda Lettmannas Vice President of Global Customer Experience,Alex Helmas Vice President Strategic Product Marketing,Stephanie Hoyleas Vice President Corporate Marketing,Amanda Hernandezas Vice President of Global Sales Training and Development,Justin Leightonas Vice President and General Manager,Lineagen, andBob Hertsenbergas North America Sales Director.</p>\n<p><b>Financial Highlights</b></p>\n<p>–<b> Total revenue for the third quarter of 2021 was$4.7 million,</b>up 21% from$3.9 millionin the second quarter and up 112% from$2.2 millionin the same period of 2020. The sequential increase was driven by increased demand for our Saphyr optical genome mapping solutions, including increased instrument sales and greater demand for our reagent rental program and consumables. The year-over-year increase was driven by both higher product sales and by the addition of revenue fromLineagen.</p>\n<p>–<b> Gross margin for the third quarter of 2021 was 24.8%,</b>compared to 37.3% in the prior quarter and 33.4% from the third quarter of 2020. The decrease was primarily due to an increase in laboratory and warranty related expense that are expected to be non-recurring.</p>\n<p>–<b> Third quarter operating expense was$21.8 million,</b>compared to$17.9 million in the prior quarter and$11.0 millionin the third quarter of 2020. The sequential increase was mainly due to a$1.8 millionincrease in headcount and related expenses and a$1.5 millionincrease in Research and Development expenses related to expanding our supply chain to produce higher volumes. Third quarter operating expense included$2.8 millionof non-cash stock-based compensation. The year-over-year increase was primarily due to increased headcount-related spending as we build out all facets of our organization to support our expected commercial progress and increased research and development costs.</p>\n<p>– <b>AtSeptember 30, 2021, the Company had cash, cash equivalents, and short-term investments of$326.1 million</b>compared to cash and cash equivalents of$38.4 millionatDecember 31, 2020. The increase in cash is primarily due to the equity raises that were completed in the first quarter of 2021.</p>\n<p><b>Remaining Anticipated Milestones for 2021 – Initiatives to Drive Global Adoption of Saphyr</b></p>\n<p>– 4Q21: Interim publication of results from pediatric clinical study</p>\n<p>– 4Q21: Validation of LDTs by 3 sites in both our prenatal clinical study and our pediatric clinical study</p>\n<p>– 4Q21: Initial prototype of next gen high throughput Saphyr</p>\n<p>– 4Q21: Reach installed base of 150 systems to achieve a 50% increase over year end 2020</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194946622","content_text":"Bionano Genomics stock tanked more than 8% in premarket trading after Bionano Genomics Q3 net loss $20.753M, sales $4.66M beat $4.23M estimate.\n\nBionano Genomics, Inc. reported financial results and business achievements for the quarter ended September 30, 2021 and highlighted recent corporate updates.\n– Acquisition of BioDiscovery transforms Bionano from the structural variation company into a data solutions provider with the potential to offer the most comprehensive variant analysis platform in genomics\n– Total revenue of$4.7 million, a 112% year-over-year total revenue increase, driven by growth in the Saphyr® installed base\n– Record number of Saphyr shipments and installations for any quarter to date\n– Launched protocols for ultra-high molecular weight DNA isolation from amniocentesis and chorionic villus sampling (CVS) for prenatal applications\n– Remaining 2021 milestones on track\n– Strong balance sheet with$326.1 millionin cash and short term investments as ofSeptember 30, 2021\n“We had the strongest quarter in Bionano’s history with a record number of Saphyr shipments and installations, including adoptions at several notable sites, including leading hospitals, cytogenetics labs and academic medical centers around the world. With the acquisition of BioDiscovery, a leading software company with best-in-class solutions for analysis, visualization, interpretation and reporting of genomics data. for microarray and next-generation sequencing (NGS), we are transitioningBionano Genomicsfrom being the structural variation company into a data solutions provider. We believe this will enable access to an expanded market opportunity by leveraging the NGS market through software. We are extremely pleased with the progress we are making and the fact that outstanding leaders are joining Bionano to join us in transforming the way the world sees the genome,” commentedErik Holmlin, PhD, Chief Executive Officer ofBionano Genomics.\nChris Stewart, Chief Financial Officer of Bionano added: “Q3 was another excellent quarter. We continued to achieve meaningful year-over-year revenue growth and maintained a strong balance sheet with$326 millionof cash and marketable securities as of the quarter-end. We also remain on track to achieve the milestones we laid out in the first quarter of 2021.”\nKey Business Highlights in Q3\nThe Company executed on its commercialization strategy, built scientific momentum by presenting data at key scientific meetings and drove utilization of Saphyr at key institutions across the globe, with the following highlights:\n– Expanded the installed base of Saphyr systems from 121 at the end of Q2 to 141 at the end of Q3. During the quarter endedSeptember 30,2021, we shipped a total of 24 Saphyr systems to the field, compared to 11 systems shipped in the same quarter in 2020.\n– Sold 3,969 nanochannel array flow cells during the quarter endedSeptember 30, 2021,which is the most flow cells sold in any quarter ever and represents 122% growth over the same quarter in 2020.\n– Commercial release of solutions for isolation of ultra-high molecular weight DNA for prenatal applicationssupporting the use of samples derived from amniocentesis and CVS. Bionano Prep SP Amnio and CVS Culture DNA Isolation Protocol supports both fresh cultures and cryopreserved cells, which expands the markets served for OGM.\n– OGM with Saphyr was adopted at several notable cytogenetics laboratories and academic medical centersinthe United States, including Brigham & Woman’s Hospital, which is using OGM to identify structural variations in constitutional and cancer applications. Outside the US, Saphyr was adopted inAustralia,EuropeandChina.\n– The largest clinical research study to date evaluating OGM was published inThe Journal of Molecular Diagnosticsfor a rare muscle disease, facioscapulohumeral muscular dystrophy, or FSHD, in about 351 patients. The results demonstrated that OGM provided data more quickly, accurately, and reproducibly than the current gold standard method of Southern blot analysis. The findings support the rationale for adopting OGM as an alternative to Southern blot analysis as OGM had a greater sizing accuracy as well as a greater than 99% concordance with Southern blot analysis.\n– NuProbe Global, a global molecular diagnostics leader, adopted Saphyr to be integrated their proprietary tools,Quantitative Amplicon Sequencing (QASeq) and Blocker Displacement Amplification (BDA), for research and development efforts in reproductive health and oncology liquid biopsies.\n– Saphyr customers and Bionano conducted 10 presentations at the Annual Cancer Genomics Consortium Meeting inmid-August 2021,highlighting the benefits of OGM for clinical research applications in solid tumor analysis, hematological malignancies, products of conception, prenatal and postnatal constitutional genetics. More than 500 participants from around the globe attended virtually, highlighting the strong interest in OGM for cancer genomics.\n– Bionano customers presented 11 presentations on OGM at theEuropean Society of Human Genetics(ESHG) meeting in lateAugust 2021, demonstrating the clinical utility of OGM across many therapeutic application areas, along with the unique capabilities of Bionano’s Saphyr®system to detect all classes of structural variants, across the genome, at a superior resolution relative to traditional techniques.\n– Added exceptional talent across commercial leadership functions,includingAmanda Lettmannas Vice President of Global Customer Experience,Alex Helmas Vice President Strategic Product Marketing,Stephanie Hoyleas Vice President Corporate Marketing,Amanda Hernandezas Vice President of Global Sales Training and Development,Justin Leightonas Vice President and General Manager,Lineagen, andBob Hertsenbergas North America Sales Director.\nFinancial Highlights\n– Total revenue for the third quarter of 2021 was$4.7 million,up 21% from$3.9 millionin the second quarter and up 112% from$2.2 millionin the same period of 2020. The sequential increase was driven by increased demand for our Saphyr optical genome mapping solutions, including increased instrument sales and greater demand for our reagent rental program and consumables. The year-over-year increase was driven by both higher product sales and by the addition of revenue fromLineagen.\n– Gross margin for the third quarter of 2021 was 24.8%,compared to 37.3% in the prior quarter and 33.4% from the third quarter of 2020. The decrease was primarily due to an increase in laboratory and warranty related expense that are expected to be non-recurring.\n– Third quarter operating expense was$21.8 million,compared to$17.9 million in the prior quarter and$11.0 millionin the third quarter of 2020. The sequential increase was mainly due to a$1.8 millionincrease in headcount and related expenses and a$1.5 millionincrease in Research and Development expenses related to expanding our supply chain to produce higher volumes. Third quarter operating expense included$2.8 millionof non-cash stock-based compensation. The year-over-year increase was primarily due to increased headcount-related spending as we build out all facets of our organization to support our expected commercial progress and increased research and development costs.\n– AtSeptember 30, 2021, the Company had cash, cash equivalents, and short-term investments of$326.1 millioncompared to cash and cash equivalents of$38.4 millionatDecember 31, 2020. The increase in cash is primarily due to the equity raises that were completed in the first quarter of 2021.\nRemaining Anticipated Milestones for 2021 – Initiatives to Drive Global Adoption of Saphyr\n– 4Q21: Interim publication of results from pediatric clinical study\n– 4Q21: Validation of LDTs by 3 sites in both our prenatal clinical study and our pediatric clinical study\n– 4Q21: Initial prototype of next gen high throughput Saphyr\n– 4Q21: Reach installed base of 150 systems to achieve a 50% increase over year end 2020","news_type":1},"isVote":1,"tweetType":1,"viewCount":1167,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":849793486,"gmtCreate":1635776244013,"gmtModify":1635776244116,"author":{"id":"3576458191145383","authorId":"3576458191145383","name":"PapiChulo88","avatar":"https://static.tigerbbs.com/c96f770d89e4ec52569d75c168c27695","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576458191145383","authorIdStr":"3576458191145383"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/HCWB\">$HCW Biologics Inc.(HCWB)$</a>Hold! It will be up again","listText":"<a href=\"https://laohu8.com/S/HCWB\">$HCW Biologics Inc.(HCWB)$</a>Hold! It will be up again","text":"$HCW Biologics Inc.(HCWB)$Hold! It will be up again","images":[{"img":"https://static.tigerbbs.com/9f78f1e45b52a24e3b5ad8e881f3d849","width":"1284","height":"2538"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/849793486","isVote":1,"tweetType":1,"viewCount":1476,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":849799713,"gmtCreate":1635776203533,"gmtModify":1635776203533,"author":{"id":"3576458191145383","authorId":"3576458191145383","name":"PapiChulo88","avatar":"https://static.tigerbbs.com/c96f770d89e4ec52569d75c168c27695","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576458191145383","authorIdStr":"3576458191145383"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NAKD\">$Naked Brand(NAKD)$</a>What’s happening ","listText":"<a href=\"https://laohu8.com/S/NAKD\">$Naked Brand(NAKD)$</a>What’s happening ","text":"$Naked Brand(NAKD)$What’s happening","images":[{"img":"https://static.tigerbbs.com/a9221a997ccd4e8a44354ac7a05795c6","width":"1284","height":"2538"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/849799713","isVote":1,"tweetType":1,"viewCount":1204,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":855989602,"gmtCreate":1635324421107,"gmtModify":1635324421107,"author":{"id":"3576458191145383","authorId":"3576458191145383","name":"PapiChulo88","avatar":"https://static.tigerbbs.com/c96f770d89e4ec52569d75c168c27695","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3576458191145383","authorIdStr":"3576458191145383"},"themes":[],"htmlText":"It’s a good time to buy ","listText":"It’s a good time to buy ","text":"It’s a good time to buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/855989602","repostId":"1105918886","repostType":4,"repost":{"id":"1105918886","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635322218,"share":"https://www.laohu8.com/m/news/1105918886?lang=&edition=full","pubTime":"2021-10-27 16:10","market":"us","language":"en","title":"Trump stocks fell sharply in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1105918886","media":"Tiger Newspress","summary":"Trump stocks fell sharply in premarket trading,Phunware slid nearly 10%,Creatd and DWAC slid over 6%","content":"<p>Trump stocks fell sharply in premarket trading,Phunware slid nearly 10%,Creatd and DWAC slid over 6%.<img src=\"https://static.tigerbbs.com/a94b366462004373a3f94a989d88dc52\" tg-width=\"285\" tg-height=\"124\" referrerpolicy=\"no-referrer\">Donald Trump has dropped from the Forbes 400 list of the richest Americans for the first time in 25 years, according to the Forbes list. Although Trump's current value of $2.5 billion is still worthy of being called \"super rich\", he is still $400 million short of the Forbes 400 Rich List in the past.</p>\n<p>Last week,Trump announced plans to set up his new social platform \"TRUTH Social\" and go public through SPAC company DWAC. While Phunware's software previously provided mobile applications for Trump campaign team.And recently,Creatd announced a new non-fungible token art drop through its OG Gallery unit consisting of three photographs of Trump. The NFT includes three candid images of a young Donald Trump, captured as he signs the breast of a model.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Trump stocks fell sharply in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTrump stocks fell sharply in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-27 16:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Trump stocks fell sharply in premarket trading,Phunware slid nearly 10%,Creatd and DWAC slid over 6%.<img src=\"https://static.tigerbbs.com/a94b366462004373a3f94a989d88dc52\" tg-width=\"285\" tg-height=\"124\" referrerpolicy=\"no-referrer\">Donald Trump has dropped from the Forbes 400 list of the richest Americans for the first time in 25 years, according to the Forbes list. Although Trump's current value of $2.5 billion is still worthy of being called \"super rich\", he is still $400 million short of the Forbes 400 Rich List in the past.</p>\n<p>Last week,Trump announced plans to set up his new social platform \"TRUTH Social\" and go public through SPAC company DWAC. While Phunware's software previously provided mobile applications for Trump campaign team.And recently,Creatd announced a new non-fungible token art drop through its OG Gallery unit consisting of three photographs of Trump. The NFT includes three candid images of a young Donald Trump, captured as he signs the breast of a model.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CRTD":"Creatd Inc","PHUN":"Phunware, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105918886","content_text":"Trump stocks fell sharply in premarket trading,Phunware slid nearly 10%,Creatd and DWAC slid over 6%.Donald Trump has dropped from the Forbes 400 list of the richest Americans for the first time in 25 years, according to the Forbes list. Although Trump's current value of $2.5 billion is still worthy of being called \"super rich\", he is still $400 million short of the Forbes 400 Rich List in the past.\nLast week,Trump announced plans to set up his new social platform \"TRUTH Social\" and go public through SPAC company DWAC. While Phunware's software previously provided mobile applications for Trump campaign team.And recently,Creatd announced a new non-fungible token art drop through its OG Gallery unit consisting of three photographs of Trump. The NFT includes three candid images of a young Donald Trump, captured as he signs the breast of a model.","news_type":1},"isVote":1,"tweetType":1,"viewCount":874,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}